Search results
Showing 7996 to 8010 of 9008 results
This guidance has been updated and replaced by NICE guideline NG60.
HIV testing: increasing uptake in men who have sex with men (PH34)
This guideline has been updated and replaced by NICE guideline NG60.
Tuberculosis: identification and management in under-served groups (PH37)
This guideline has been updated and replaced by NICE guideline NG33.
This guideline has been updated and replaced by NICE guideline NG92.
This guideline has been updated and replaced by the NICE guideline on social, emotional and mental wellbeing in primary and secondary education (NG223).
Lutonix drug-coated balloon for peripheral arterial disease (MIB72)
NICE withdrew this medtech innovation briefing in October 2019 after the MHRA withdrew support for this type of technology being used in intermittent claudication for arterial disease.
This medtech innovation briefing is temporarily unavailable, please contact mibs@nice.org.uk for further information.
Endoluminal gastroplication for gastro-oesophageal reflux disease (IPG404)
Interventional procedures, IPG404 - Issued: July 2011 --> This guidance has been updated and replaced by NICE HealthTech guidance 661.
Interventional procedures, IPG418 - Issued: January 2012 --> This guidance has been updated and replaced by NICE HealthTech guidance 662.
In development Reference number: GID-TA11581 Expected publication date: TBC
This guidance has been updated and replaced by NICE's technology appraisal guidance on bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer (TA1136).
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)
This guidance has been updated and replaced by NICE's technology appraisal guidance on cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242) and bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer (TA1136).
Discontinued Reference number: GID-TA10843
This guidance has been withdrawn because Cartiva Synthetic Cartilage Implant (SCI) has been recalled, and the evidence for this guidance was based solely on Cartiva SCI. More information is available in the field safety notice issued by Stryker. Surgeons are advised not to implant this device, to return any unused devices to Stryker and to consider reviewing any patients who have had Cartiva SCI. NICE will consider issuing new guidance on synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus) if evidence using an appropriately CE-marked device becomes available.
Leadless cardiac pacemaker implantation for bradyarrhythmias (HTG484)
This guidance has been updated and replaced by NICE HealthTech guidance 770.